logo-loader
viewCB2 Insights Inc.

CB2 Insights to study effects of hemp CBD on patients with anxiety in partnership with GL Brands

The trial will measure safety, efficacy and other health measures for patients using Green Lotus brand CBD soft gel capsules for anxiety

Person in scrubs holding cannabis and oil
CB2 will recruit patients and clinicians from its existing network, which the company said is the largest medical cannabis patient registry in the US

CB2 Insights Inc (CSE:CBII) (OTCMKTS:CBIIF), a medical cannabis research and technology company, is launching a study to test the effects of hemp-based CBD on patients with anxiety. 

The study, which CB2 said is the first of its kind, is being done in partnership with US hemp consumer goods company GL Brands (OTCQB:FRLF), through its subsidiary Green Lotus. The trial will measure safety, efficacy and other health measures for patients using Green Lotus brand CBD soft gel capsules to treat anxiety. 

“We are proud to have been approached by GL Brands to help advance their product research and development efforts using our vast network of clinical sites and knowledge and experience in conducting clinical trials,” CB2 CEO Prad Sekar said in a statement. 

READ: CB2 Insights set to launch cloud-based platform Sail in 2020

“Cannabis licensed producers, product manufacturers and cannabis-focused pharmaceutical companies have all matured to the point of needing clinically-driven research to support the registration of their medical products,” Sekar added. “Our tools and experience help formalize and expedite that process in a way that is aligned with traditional pharmaceutical products.”

To get the study up and running, CB2 will recruit patients and clinicians from its existing network, which the company said is the largest medical cannabis patient registry in the US. 

The design of the study will include a multi-center experimental pre-test, post-test, non-randomized design and will monitor patients using the specified Green Lotus treatment over a 90-day period.

“Through our subsidiary brand, Green Lotus, we have brought to market one of the most wide-ranging lines of natural and organic hemp products that provide a full spectrum of remedies for consumers across North America suffering from multiple ailments,” GL Brands CEO Carlos Frias said. “Our partnership with CB2 Insights will allow us to illustrate the effectiveness of our products across indications such as chronic pain, sleep disorders and anxiety.”

GL Brands, formerly known as Freedom Leaf, produces a variety of cannabinoid-rich products under its Green Lotus and IrieCBD brand names.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: CB2 Insights Inc.

Price: 0.095 CAD

CSE:CBII
Market: CSE
Market Cap: $7.87 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CB2 Insights announces key partnership with GL Brands for...

CB2 Insights ((CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules...

on 17/12/19

2 min read